Evaluation of two different metabolic hypotheses for dichloromethane toxicity using physiologically based pharmacokinetic modeling for in vivo inhalation gas uptake data exposure in female B6C3F1 mice

Toxicology and Applied Pharmacology

Volumn 244, Issue 3, 2010, Pages 280-290

  Evans, M V ^a   Caldwell, J C ^b  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Atypical CYP kinetics; DCM; Dichloromethane; Metabolism; Methylene chloride; Physiologically based pharmacokinetic (PBPK) model

Indexed keywords

CYTOCHROME P450 2E1; DICHLOROMETHANE; DNA; GLUTATHIONE; SOLVENT;

ANIMAL EXPERIMENT; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DNA ADDUCT; DNA DAMAGE; ENZYME ACTIVE SITE; ENZYME CONFORMATION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG ALVEOLUS CELL; LUNG TOXICITY; METABOLIC RATE; MOUSE; NONHUMAN; TOXICOKINETICS; ANIMAL; ANIMAL MODEL; BINDING SITE; CHEMICAL MODEL; DRUG EFFECT; EXPOSURE; METABOLISM;

MUS;

ANIMALS; BINDING SITES; CYTOCHROME P-450 CYP2E1; FEMALE; GLUTATHIONE; INHALATION EXPOSURE; METABOLIC NETWORKS AND PATHWAYS; METHYLENE CHLORIDE; MICE; MODELS, ANIMAL; MODELS, CHEMICAL; SOLVENTS;

EID: 77950493170     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2010.01.018     Document Type: Article

References (44)

1. Anders M.W. Chemical toxicology of reactive intermediates formed by the glutathione-dependent bioactivation of halogen-containing compounds. Chem. Res. Toxicol. 2008, 21:145-159.
2. Andersen M.E., Clewell H.J., Gargas M.L., Smith F.A., Reitz R.H. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol. Appl. Pharmacol. 1987, 87:185-205.
3. Andersen M.E., Clewell H.J., Mahle D.A., Gearhart J.M. Gas uptake studies of deuterium isotope effects on dichloromethane metabolism in female B6C3F1 mice in vivo. Toxicol. Appl. Pharmacol. 1994, 128:158-165.
4. Angelo M.J., Bischoff K.B., Pritchard A.B., Presser M.A. A physiological model for the pharmacokinetics of methylene chloride in B6C3F1 mice following i.v. administrations. J. Pharmacokinet. Biopharm. 1984, 12:413-436.
5. Angelo M.J., Pritchard A.B., Hawkins D.R., Waller A.R., Roberts A. The pharmacokinetics of dichloromethane: I. Diposition in B6C3F1 mice following intravenous and oral administration. Food Chem. Toxicol. 1986, 24(9):965-974.
6. Angelo M.J., Prichard A.B., Hawkins D.R., Waller A.R., Roberts A. The pharmacokinetics of dichloromethane: II. Disposition in Fischer 344 rats following intravenous and oral administration. Food Chem. Toxicol. 1986, 24(9):975-980.
7. Atkins G.L., Nimmo I.A. The reliability of Michaelis constants and maximum velocities estimated by using the integrated Michaelis-Menten equation. Biochem. J. 1973, 135:779-784.
8. Brown R.P., Delp M.D., Lindstedt S.L., Rhomberg L.R., Beliles R.P. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 1997, 13:407-484.
9. Clewell, H.J., III, Gearhart, J.M., and Andersen, M.E. (1993). Analysis of the metabolism of methylene chloride in the B6C3F1 mouse and its implications for human risk assessment. Submission to OSHA 96.
10. David R.M., Clewell H.J., Gentry P.R., et al. Revised assessment of cancer risk to dichloromethane II. Application of probabilistic methods to cancer risk determinations. Regul. Toxicol. Pharmacol. 2006, 45:55-65.
11. El-Masri H.A., Dowd S.M., Pegram R.A., Harrison R.A., Yavanhxay S., Simmons J.E., Evans M.V. Development of an inhalation physiologically-based pharmacokinetic (PBPK) model for 2,2,4-trimethylpentane (TMP) in male Long Evans rats using gas uptake experiments. Inhal. Toxicol. 2009, 21:1176-1185. DOI:10.3109/08958370903005751.
12. Evans M.V., Andersen M.E. Sensitivity analysis and the design of gas uptake inhalation studies. Inhal. Toxicol. 1995, 7:1075-1094.
13. Evans M.V., Chiu W.A., Okino M.S., Caldwell J.C. Development of an updated PBPK model for trichloroethylene and metabolites in mice, and its application to discern the role of oxidative metabolism in TCE-induced hepatomegaly. Toxicol. Appl. Pharmacol. 2009, 236:329-340.
14. Gargas M.L., Clewell H.J., Andersen M.E. Metabolism of inhaled dihalomethanes in vivo: differentiation of kinetic constants for two independent pathways. Toxicol. Appl. Pharmacol. 1986, 82:211-223.
15. Guengerich F.P., Kim D.H., Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol. 1991, 4:168-179.
16. Guengerich F.P., McCormick W.A., Wheeler J.B. Analysis of the kinetic mechanism of haloalkane conjugation by mammalian theta-class glutathione transferases. Chem. Res. Toxicol. 2003, 16:1493-1499.
17. Halllier E., Schröder K.R., Asmuth K., Dommermuth A., Aust B., Werner Goergens H. Metabolism of dichloromethane (methylene chloride) to formaldehyde in human erythrocytes: influence of polymorphisms of glutathione transferase Theta (GST T1-1). Arch. Toxicol. 1994, 68:423-427.
18. Harrelson J.P., Atkins W.M., Nelson S.D. Multiple-ligand binding in CYP2A6: probing mechanisms of cytochrome P450 cooperativity by assessing substrate dynamics. Biochemistry 2008, 47:2978-2988.
19. Harrelson J.P., Henne K.R., Alonso D.O., Nelson S.D. A comparison of substrate dynamics in human CYP2E1 and CYP2A6. Biochem. Biophys. Res. Commun. 2007, 352:843-849.
20. Hazelton Laboratories, (1983) 24-Month oncogenicity study of methylene chloride in mice [final report]. Performed by Hazelton Laboratories America, Inc., Vienna, VA for the National Coffee Association, New York, NY; Submitted under TSCA Section 4; EPA Document No. 45-8303005; NTIS No. OTS0206132.
21. IARC (International Agency for Research on Cancer), (1999) Dichloromethane. IARC monographs on the evaluation of carcinogenic risk of chemicals to humans. Vol. 71. Re-evaluation of some organic chemicals, hydrazine and hydrogen peroxide. Lyon, France: International Agency for Research on Cancer, pp. 251-315. Available online at http://inchem.org/documents/iarc/vol71/004-dichloromethane.html.
22. Kirschman J.C., Brown N.M., Coots R.H., Morgareidge K. Review of investigations of dichloromethane metabolism and subchronic oral toxicity as the basis for the design of chronic oral studies in rats and mice. Food Chem. Toxicol. 1986, 24(9):943-949.
23. Korzekwa K.R., Krishnamachary N., Shou M., Ogai A., Parise R.A., Rettie A.E., Gonzalez F.J., Tracy T.S. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 1998, 37:4137-4147.
24. Landi S., Naccarati A., Ross M.K., Hanley N.M., Dailey L., Devlin R.B., Vasquez M., Pegram R.A., DeMarini D.M. Induction of DNA strand breaks by trihalomethanes in primary human lung epithelial cells. Mutat. Res. 2003, 538:41-50.
25. Lilly P.D., Thornton-Manning J.R., Gargas M.L., Clewell H.J., Andersen M.E. Kinetic characterization of CYP2E1 inhibition in vivo and in vitro by the chloroethylenes. Arch. Toxicol. 1998, 72:609-621.
26. Maltoni C., Cotti G., Perino G. Long-term carcinogenicity bioassays on methylene chloride administered by ingestion to Sprague-Dawley rats and Swiss mice and by inhalation to Sprague-Dawley rats. Ann. N.Y. Acad. Sci. 1988, 534:352-366.
27. Marino D.J., Clewell H.J., Gentry P.R., Covington T.R., Hack C.E., David R.M., Morgott D.A. Revised assessment of cancer risk to dichloromethane: Part I. Bayesian PBPK and dose-response modeling in mice. Regul. Toxicol. Pharmacol. 2006, 45:44-54.
28. Mathews J.M., Etheridge A.S., Raymer J.H., Black S.R., Pulliam D.W., Bucher J.R. Selective inhibition of cytochrome P450 2E1 in vivo and in vitro with trans-1,2-dichloroethylene. Chem. Res. Toxicol. 1998, 11:778-785.
29. 1 mice. Ann. N.Y. Acad. Sci. 1988, 534:343-351.
30. Nitschke K.D., Burek J.D., Bell T.J., et al. Methylene chloride: a 2-year inhalation toxicity and oncogenicity study in rats. Fundam. Appl. Toxicol. 1988, 11:48-59.
31. Toxicology and carcinogenesis studies of dichloromethane (methylene chloride) (CAS No. 75-09-2) in F344/N rats and B6C3F1 mice (inhalation studies). Natl. Toxicol. Program Tech. Rep. Ser. 1986, 306:1-208. NTP (National Toxicology Program).
32. Porubsky P.R., Meneely K.M., Scott E.E. Structures of human cytochrome P-450 2E1. Insights into the binding of inhibitors and both small molecular weight and fatty acid substrates. J. Biol. Chem. 2008, 283:33698-33707. Electronic publication 2008. Sep. 24.
33. Ramsey J.C., Andersen M.E. A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. Toxicol. Appl. Pharmacol. 1984, 73:159-175.
34. Reitz R.H., Mendrala A.L., Guengerich F.P. In vitro metabolism of methylene chloride in human and animal tissues: use in physiologically based pharmacokinetic models. Toxicol. Appl. Pharmacol. 1989, 97:230-246.
35. Ruder A.M. Potential health effects of occupational chlorinated solvent exposure. Ann. N. Y. Acad. Sci. 2006, 1076:207-227.
36. Segel I.H. Enzyme kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems 1993, Wiley Classics, New York.
37. Serota D.G., Thakur A.K., Ulland B.M., et al. A two-year drinking water study of dichloromethane in rodents: I. Rats. Food. Chem. Toxicol. 1986, 24(9):951-958.
38. Serota D.G., Thakur A.K., Ulland B.M., et al. A two-year drinking water study of dichloromethane in rodents: II. Mice. Food. Chem. Toxicol. 1986, 24(9):959-963.
39. Slikker W., Andersen M.E., Bogdanffy M.S., Bus J.S., Cohen S.D., Conolly R.B., David R.M., Doerrer N.G., Dorman D.C., Gaylor D.W., Hattis D., Rogers J.M., Woodrow Setzer R., Swenberg J.A., Wallace K. Dose-dependent transitions in mechanisms of toxicity. Toxicol. Appl. Pharmacol. 2004, 201:203-225.
40. Sweeney L.M., Kirman C.R., Morgott D.A., Gargas M.L. Estimation of interindividual variation in oxidative metabolism of dichloromethane in human volunteers. Toxicol. Lett. 2004, 154:201-216.
41. Thier R., Taylor J.B., Pemble S.E., Humphreys W.G., Persmark M., Ketterer B., Guengerich F.P. Expression of mammalian glutathione S-transferase 5-5 in Salmonella typhimurium TA1535 leads to base-pair mutations upon exposure to dihalomethanes. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:8576-8580.
42. Tracy T.S. Atypical cytochrome p450 kinetics: implications for drug discovery. Drugs R. D. 2006, 7:349-363.
43. Watanabe K., Guengerich F.P. Limited reactivity of formyl chloride with glutathione and relevance to metabolism and toxicity of dichloromethane. Chem. Res. Toxicol. 2006, 19:1091-1096.
44. Watanabe K., Liberman R.G., Skipper P.L., Tannenbaum S.R., Guengerich F.P. Analysis of DNA adducts formed in vivo in rats and mice from 1,2-dibromoethane, 1,2-dichloroethane, dibromomethane, and dichloromethane using HPLC/accelerator mass spectrometry and relevance to risk estimates. Chem. Res. Toxicol. 2007, 20:1594-1600.